ImmunoCellular Therapeutics Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and ImmunoCellular Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days ImmunoCellular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, ImmunoCellular Therapeutics is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
ImmunoCellular |
ImmunoCellular Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in ImmunoCellular Therapeutics on December 4, 2024 and sell it today you would earn a total of 100.00 from holding ImmunoCellular Therapeutics or generate -100.0% return on investment over 90 days. ImmunoCellular Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than ImmunoCellular, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ImmunoCellular Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImmunoCellular Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as ImmunoCellular Therapeutics, and traders can use it to determine the average amount a ImmunoCellular Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| IMUC |
Based on monthly moving average ImmunoCellular Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ImmunoCellular Therapeutics by adding ImmunoCellular Therapeutics to a well-diversified portfolio.
ImmunoCellular Therapeutics Fundamentals Growth
ImmunoCellular Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of ImmunoCellular Therapeutics, and ImmunoCellular Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImmunoCellular Pink Sheet performance.
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 | ||||
| Current Valuation | (1.69 M) | ||||
| Shares Outstanding | 4.19 M | ||||
| Price To Earning | 0.02 X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (6.07 M) | ||||
| Cash And Equivalents | 933.15 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 2.78 M | ||||
| Debt To Equity | 0.39 % | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (2.31 M) | ||||
| Earnings Per Share | 28.91 X | ||||
| Total Asset | 30.08 M | ||||
| Retained Earnings | (74.14 M) | ||||
| Current Asset | 24.56 M | ||||
| Current Liabilities | 2.27 M | ||||
Things to note about ImmunoCellular Therapeutics performance evaluation
Checking the ongoing alerts about ImmunoCellular Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for ImmunoCellular Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImmunoCellular Therapeutics is not yet fully synchronised with the market data | |
| ImmunoCellular Therapeutics has some characteristics of a very speculative penny stock | |
| ImmunoCellular Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ImmunoCellular Therapeutics currently holds about 933.15 K in cash with (2.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 95.0% of the company shares are held by company insiders |
- Analyzing ImmunoCellular Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImmunoCellular Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining ImmunoCellular Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImmunoCellular Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImmunoCellular Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImmunoCellular Therapeutics' pink sheet. These opinions can provide insight into ImmunoCellular Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |